You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Called the Integrated Proteomics Pipeline, the platform offers search engine capabilities that will enable better use of collision cross section data.
Investigators identified disease-associated histone modifications in the brain that appeared to influence transcription- and chromatin-related processes.
Investors included Bruker, whose MALDI mass spectrometry imaging platforms could have synergies with Ionpath's Multiplexed Ion Beam Imaging technology.
Planned and ongoing studies will use standardized plasma protein profiling workflows to discover biomarkers for a range of conditions.
Instead of measuring metabolites directly, the researchers used mass cytometry and multiplexed ion beam imaging to measure proteins involved in metabolic regulation.
Working with ETH Zurich researchers, the firm has incorporated machine learning to improve the platform's performance in complex organisms like humans.
The method uses DIA mass spec runs to adjust for drifts in LC retention times, allowing researchers to schedule more highly multiplexed experiments.
The firm said it plans to use the proceeds to support the launch of its first product based on its structures for lossless ion manipulation ion mobility system.
Recently developed deep learning tools and other software packages have streamlined DIA mass spec workflows and are driving uptake within proteomics cores.
The pair are working on reagents and mass spec approaches to improve isolation and analysis of crosslinked peptides for protein interaction and structural studies.
The Singapore-based company will use the funds to expand its presence in the US and develop its platform, which uses mass cytometry to profile T-cell response.
The collaborators will develop methods using Bruker's timsTOF Pro for structural and protein interaction work that the company plans to commercialize.
The tests use a range of different specimens including self-collected nasal swabs, bronchoalveolar lavage, sputum, and nasopharyngeal washes.
The company reported Q2 revenues of $424.6 million, down from $490.2 million in Q2 2019 but beating the consensus Wall Street estimate of $390.9 million.
The company posted Q2 revenues of $520.0 million, down 13 percent from $599.2 million in Q2 2019, but above analysts' average estimate of $496.9 million.
The company said that the better-than-expected projections were driven mainly by stronger demand for its life science products.
Bruker's system has seen strong uptake among proteomics researchers, but its ability to generate large amounts of complex data has led to analysis challenges.
The firm's predicted Q2 revenues of $517 million to $523 million beat expectations as former MilliporeSigma CEO Udit Batra becomes president and CEO.
The platform combines Leica's laser microdissection tool and PBI's pressure cycling tech to enable better extraction and digestion of proteins from biopsies.
The work suggests mass spec can more accurately assess levels of immunotherapy targets like PD-L1 than conventional clinical approaches.
Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.
NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
In Science this week: review discusses advances in liquid biopsies, and more.